CAMBRIDGE, England--(BUSINESS WIRE)--Bicycle Therapeutics Ltd, a new biotechnology company developing a novel technology platform for the identification and optimisation of chemically constrained cyclic peptides with high target specificity and binding affinity, has signed a License agreement with the Ecole Polytechnique Federale de Lausanne (EPFL) in Lausanne, Switzerland and has secured additional seed funding from SR One, the independent corporate venture fund of GlaxoSmithKline, and SV Life Sciences.
Bicycle Therapeutics is a spin-out from the MRC Laboratory of Molecular Biology, Cambridge and is based at the Babraham Research Campus in Cambridge, UK. Its technology platform is based on the pioneering work at the LMB of the founding scientists Sir Gregory Winter, a scientific founder of both CAT and Domantis, and Dr. Christian Heinis. Christian Heinis is currently Assistant Professor at the Institute of Chemical Sciences and Engineering (ISIC) at EPFL and the License Agreement with EPFL cements the ongoing relationship between Bicycle and his laboratory. The founding investors for Bicycle, Atlas Venture and Novartis Venture Fund, are now joined by SR One and SVLS to complete the seed phase investment syndicate.
“We are delighted to have signed this agreement with EPFL and the addition of such highly respected investors such as SR One and SVLS to the seed phase syndicate is a massive endorsement of the potential of the company and will allow the company to accelerate its growth ’’ said John Tite , CEO of Bicycle Therapeutics.
Sir Greg Winter commented "Christian Heinis and his group are doing some very elegant work at EPFL on bicyclic peptides; I am delighted that Bicycle Therapeutics will now have the ability to benefit from access to this work."
‘’Through the innovative scientific activities of Prof Heinis and this license agreement, EPFL is proud to be associated to the creation and initial development of Bicycle Therapeutics. We consider this signature as a first step to further fruitful scientific cooperation with this very promising spin-out and with MRC ’’ said Gabriel Clerc, Head of the Technology Transfer Office at EPFL.
Since its formation the company has moved into its new premises at the Babraham Research Campus in Cambridge, U.K. Dr Debbie Harland, SR One and Kate Bingham, SVLS have joined the Board of Directors of Bicycle.
About Bicycle Therapeutics
Bicycle Therapeutics is a biotechnology company based at the Babraham Research Campus in Cambridge, U.K. developing a novel technology for the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals. Bicycle technology is based on the work performed at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Prof. Christian Heinis and Prof. Sir Gregory Winter and is managed by Dr John Tite (CEO). The company was founded in July 2009 and received initial seed funding from Atlas Venture and Novartis Venture Fund. For more information visit www.bicycletherapeutics.com
EPFL is one of the two Ecoles Polytechniques Fédérales in Switzerland. It has three missions: education, research and technology transfer at the highest international level. With more than 250 laboratories and research groups on campus, EPFL is one of Europe's most innovative and productive technology institutes. Its unique structure facilitates transdisciplinary research and encourages partnerships with other academic institutions as well as with industry and it supports new emerging businesses. EPFL emphasizes both fundamental research and applied research. For more information visit www.epfl.ch
About SR One
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. For more information visit www.srone.com
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. For more information visit www.svlsa.com